PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23912708-9 2013 Moreover, the induction of apoptosis by TRAIL plus cisplatin was accompanied by the downregulation of cFLIP and BCL2L1, and simultaneously robust enzymatic activation of caspase-8, culminating in decreased cancer cell survival. Cisplatin 51-60 CASP8 and FADD like apoptosis regulator Homo sapiens 102-107 23313194-0 2013 The role of c-FLIP in cisplatin resistance of human bladder cancer cells. Cisplatin 22-31 CASP8 and FADD like apoptosis regulator Homo sapiens 12-18 23313194-3 2013 Changes in cisplatin sensitivity by c-FLIP knockdown and related mechanisms in T24R2 cells were assessed using the Cell Counting Kit-8 assay (Dojindo Molecular Technologies, Gaithersburg, Maryland) and Western blot. Cisplatin 11-20 CASP8 and FADD like apoptosis regulator Homo sapiens 36-42 23313194-7 2013 Western blot demonstrated complete cisplatin mediated suppression of c-FLIP expression in T24 cells but no change in c-FLIP expression was observed in T24R2 cells after cisplatin treatment in the same dose range. Cisplatin 35-44 CASP8 and FADD like apoptosis regulator Homo sapiens 69-75 23313194-8 2013 Suppression of c-FLIP expression in T24R2 cells by siRNA transfection rendered these cells significantly more sensitive to cisplatin treatment than untransfected T24R2 cells (p <0.05). Cisplatin 123-132 CASP8 and FADD like apoptosis regulator Homo sapiens 15-21 23313194-9 2013 CONCLUSIONS: Results reveal that c-FLIP has an important role in the cisplatin resistance of human bladder cancer cells and c-FLIP modulation may at least partially reverse cisplatin resistance in bladder cancer cells. Cisplatin 69-78 CASP8 and FADD like apoptosis regulator Homo sapiens 33-39 23313194-9 2013 CONCLUSIONS: Results reveal that c-FLIP has an important role in the cisplatin resistance of human bladder cancer cells and c-FLIP modulation may at least partially reverse cisplatin resistance in bladder cancer cells. Cisplatin 173-182 CASP8 and FADD like apoptosis regulator Homo sapiens 124-130 21877938-0 2011 Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cisplatin 0-9 CASP8 and FADD like apoptosis regulator Homo sapiens 130-136 21877938-3 2011 However, treatment with cisplatin leads to the upregulation of DR5 and downregulation of c-FLIP and restores TRAIL apoptotic pathway in the neurospheres. Cisplatin 24-33 CASP8 and FADD like apoptosis regulator Homo sapiens 89-95 18559494-2 2008 Although p53 and FLICE-like inhibitory protein (FLIP) are determinants of CDDP sensitivity in ovarian cancer, the interaction between p53 and FLIP remains poorly understood. Cisplatin 74-78 CASP8 and FADD like apoptosis regulator Homo sapiens 17-46 20876774-10 2011 Overexpression of c-FLIP(L) rescues cells from 5-FU- or cisplatin-mediated sensitisation for TRAIL-induced apoptosis, indicating that c-FLIP suppression is a key event in this chemotherapy-mediated sensitisation to TRAIL. Cisplatin 56-65 CASP8 and FADD like apoptosis regulator Homo sapiens 18-24 20876774-10 2011 Overexpression of c-FLIP(L) rescues cells from 5-FU- or cisplatin-mediated sensitisation for TRAIL-induced apoptosis, indicating that c-FLIP suppression is a key event in this chemotherapy-mediated sensitisation to TRAIL. Cisplatin 56-65 CASP8 and FADD like apoptosis regulator Homo sapiens 134-140 18675507-5 2008 Furthermore, Vector-based shRNA against c-FLIP subsequently increased the sensitivity to cisplatin, iritican and Co60 radiotherapy by about 4- to 6-folds in Hela cells. Cisplatin 89-98 CASP8 and FADD like apoptosis regulator Homo sapiens 40-46 17973862-0 2007 Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation. Cisplatin 82-91 CASP8 and FADD like apoptosis regulator Homo sapiens 114-120 17973862-11 2007 Treatment of resistant cells with 100 micromol/L KN-93 and 10 microg/mL cisplatin downregulated c-FLIP expression, inhibited c-FLIP phosphorylation and rescued CH-11 sensitivity. Cisplatin 72-81 CASP8 and FADD like apoptosis regulator Homo sapiens 96-102 17973862-11 2007 Treatment of resistant cells with 100 micromol/L KN-93 and 10 microg/mL cisplatin downregulated c-FLIP expression, inhibited c-FLIP phosphorylation and rescued CH-11 sensitivity. Cisplatin 72-81 CASP8 and FADD like apoptosis regulator Homo sapiens 125-131 17973862-13 2007 In conclusion, KN-93 and cisplatin inhibit c-FLIP protein expression and phosphorylation restores CH-11-induced apoptosis in tumour cells. Cisplatin 25-34 CASP8 and FADD like apoptosis regulator Homo sapiens 43-49 14519653-8 2003 Instead, cisplatin treatment down-regulated intracellular expression of the short form of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein (c-FLIP) and inhibited phosphorylation of the long form of c-FLIP. Cisplatin 9-18 CASP8 and FADD like apoptosis regulator Homo sapiens 193-199 17693058-9 2007 Treatment of the resistant cells with camptothecin, celecoxib and cisplatin resulted in the downregulation of c-FLIP and caused a synergistic apoptotic effect with TRAIL. Cisplatin 66-75 CASP8 and FADD like apoptosis regulator Homo sapiens 110-116 15644494-0 2005 Cross-resistance to death ligand-induced apoptosis in cisplatin-selected HeLa cells associated with overexpression of DDB2 and subsequent induction of cFLIP. Cisplatin 54-63 CASP8 and FADD like apoptosis regulator Homo sapiens 151-156 14519653-8 2003 Instead, cisplatin treatment down-regulated intracellular expression of the short form of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein (c-FLIP) and inhibited phosphorylation of the long form of c-FLIP. Cisplatin 9-18 CASP8 and FADD like apoptosis regulator Homo sapiens 251-257 14519653-9 2003 CONCLUSIONS: The results presented here indicate that cisplatin inhibits c-FLIP protein expression and phosphorylation to restore TRAIL-induced caspase-8-initiated apoptosis in melanoma cells, thus providing a new combined therapeutic strategy for melanomas. Cisplatin 54-63 CASP8 and FADD like apoptosis regulator Homo sapiens 73-79 12845662-9 2003 These results suggest that CDDP and 5-FU may enhance the susceptibility to Fas-mediated apoptosis through down-regulation of c-FLIP. Cisplatin 27-31 CASP8 and FADD like apoptosis regulator Homo sapiens 125-131 12919886-8 2003 CDDP down-regulated c-FLIP, tending to lower the activation threshold required for TRAIL-induced caspase-8 activation. Cisplatin 0-4 CASP8 and FADD like apoptosis regulator Homo sapiens 20-26 33302576-0 2020 Inhibition of Drp1 Sensitizes Cancer Cells to Cisplatin-Induced Apoptosis through Transcriptional Inhibition of c-FLIP Expression. Cisplatin 46-55 CASP8 and FADD like apoptosis regulator Homo sapiens 112-118 12642689-2 2002 We have observed that exogenous expression of MRITalpha1/cFLIP(L) isoform also protects against cell death induced by a diverse group of chemotherapeutic drugs with different mechanisms of action, including doxorubicin, etoposide, cytosine arabinoside, daunorubicin, chlorambucil and cisplatin. Cisplatin 284-293 CASP8 and FADD like apoptosis regulator Homo sapiens 57-62 33302576-7 2020 Combined treatment induced downregulation of c-FLIP expression transcriptionally, and ectopic expression of c-FLIP attenuated combined treatment-induced apoptotic cell death with mdivi-1 plus cisplatin. Cisplatin 192-201 CASP8 and FADD like apoptosis regulator Homo sapiens 108-114 26273359-7 2015 Treatment with TSA and cisplatin led to a significant decrease of cFLIP expression. Cisplatin 23-32 CASP8 and FADD like apoptosis regulator Homo sapiens 66-71 31838086-0 2020 Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. Cisplatin 0-9 CASP8 and FADD like apoptosis regulator Homo sapiens 90-96 31838086-6 2020 Efficacy of the combined treatment relied on cisplatin-induced downregulation of c-FLIP, the main regulator of the extrinsic apoptotic pathway, leading to an enhanced caspase-8-mediated pathway. Cisplatin 45-54 CASP8 and FADD like apoptosis regulator Homo sapiens 81-87 28863158-0 2017 c-FLIP and the NOXA/Mcl-1 axis participate in the synergistic effect of pemetrexed plus cisplatin in human choroidal melanoma cells. Cisplatin 88-97 CASP8 and FADD like apoptosis regulator Homo sapiens 0-6 28863158-7 2017 Furthermore, the expression levels of c-FLIP, an anti-apoptotic protein in the extrinsic apoptosis pathway, and Mcl-1, an anti-apoptotic protein in the intrinsic apoptosis pathway, were decreased by pemetrexed or cisplatin respectively, while the expression of a pro-apoptotic protein in the intrinsic apoptosis pathway, NOXA, was up-regulated. Cisplatin 213-222 CASP8 and FADD like apoptosis regulator Homo sapiens 38-44 28863158-14 2017 To summarize, the c-FLIP and NOXA/Mcl-1 axis participated in the synergistic effect of pemetrexed plus cisplatin in human choroidal melanoma cells. Cisplatin 103-112 CASP8 and FADD like apoptosis regulator Homo sapiens 18-24 25682199-0 2015 Synergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagy-mediated apoptosis. Cisplatin 33-42 CASP8 and FADD like apoptosis regulator Homo sapiens 83-90 25682199-8 2015 These results establish a novel mechanism for potentiation of anticancer activity with the combination of Chal-24 and cisplatin: to enhance apoptosis signaling through Ripoptosome formation and to release the apoptosis brake through c-FLIPL degradation. Cisplatin 118-127 CASP8 and FADD like apoptosis regulator Homo sapiens 233-240